1. Home
  2. ARVN vs NXP Comparison

ARVN vs NXP Comparison

Compare ARVN & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.04

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Select Tax Free Income Portfolio

NXP

Nuveen Select Tax Free Income Portfolio

HOLD

Current Price

$14.28

Market Cap

744.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
NXP
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
658.2M
744.2M
IPO Year
2018
1995

Fundamental Metrics

Financial Performance
Metric
ARVN
NXP
Price
$8.04
$14.28
Analyst Decision
Buy
Analyst Count
19
0
Target Price
$15.05
N/A
AVG Volume (30 Days)
680.3K
129.2K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
N/A
N/A
Revenue
$262,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.06
$13.73
52 Week High
$14.22
$14.65

Technical Indicators

Market Signals
Indicator
ARVN
NXP
Relative Strength Index (RSI) 46.65 50.36
Support Level $7.35 $14.22
Resistance Level $10.18 $14.51
Average True Range (ATR) 0.41 0.11
MACD 0.17 -0.00
Stochastic Oscillator 70.20 53.47

Price Performance

Historical Comparison
ARVN
NXP

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About NXP Nuveen Select Tax Free Income Portfolio

Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.

Share on Social Networks: